SAN DIEGO—University of California researchers announced on Nov. 12 that they, together with colleagues from other institutions, are assessing whether medicinal mushrooms and Chinese herbs can provide therapeutic benefit in treating acute COVID-19 infection.
This research study, “Mushrooms and Chinese Herbs for COVID-19” (MACH-19), is a multi-center effort led by the University of California–San Diego (UCSD) and University of California–Los Angeles, along with the La Jolla Institute for Immunology. It is among the first to evaluate these medicines using a randomized, double-blind, placebo-controlled clinical trial.
“We hope these treatments will reduce the need for hospitalization,” said MACH-19 principal investigator Dr. Gordon Saxe, director of research at the Centers for Integrative Health at UCSD School of Medicine.
Three trials are recruiting for between 66 and 80 patients who have tested positive for COVID-19 and who are quarantined at home with mild to moderate symptoms.
One of the studies, which started in December and is slated to run until December 2022, tests the safety and feasibility of a 50/50 blend of the mushrooms agarikon and turkey tail in capsules.
According to Saxe, the mushrooms were chosen because of their long history of use and recent evidence of immunity-enhancing and anti-viral effects.
In a study published in the March 2019 issue of Mycology, agarikon was found to inhibit viruses, including influenza and herpes. Saxe said he believes medicinal mushrooms inhibit the viruses’ replication, a theory he plans to test against SARS-CoV-2 in a Phase II trial.
“Mushrooms have the advantage that they co-evolved with us,” Saxe said. “So bacteria, viruses, and other fungi prey on mushrooms just like they prey on humans. And mushrooms have developed exquisite defenses against those pests, and we believe they can confer those to us when we eat them.”
The second trial, which began in July and is projected to conclude in December 2022, tests the safety and feasibility of a formulation of 21 Chinese herbs from Taiwan—called Qing Fei Pai Du Tang—that is widely used as a COVID-19 remedy in China.
MACH-19’s third ongoing trial, which began in June and is scheduled for completion in June 2022, measures whether the same medicinal mushrooms, given in capsules at the time of initial COVID-19 vaccination, can increase antibodies and other immune responses.
Saxe said his team is close to launching a fourth trial to look at whether medicinal mushrooms could provide a similar lift to COVID-19 booster shots.
“Vaccines lead to the production of antibodies that can destroy the virus in the blood,” Saxe said. “Mushrooms may not only increase the number of these antibodies, but also enhance T-cell immunity against virally infected cells.
“Further, because mushrooms bind to receptors on human immune cells, they can modulate our immunity, boosting it in some ways and calming it down in others,” he said. “And this property of mushrooms may also reduce vaccine-related side effects.”
Natural therapeutics have been used for centuries to treat infectious diseases, Saxe said, noting that herbs have helped Chinese doctors manage 300 recorded epidemics, while the Greek pharmacologist Pedanius Dioscorides prescribed agarikon to treat pulmonary infections 2,300 years ago.
Initial safety data from the trials are expected by the end of this year. Whatever is found, Saxe said he was happy just getting the FDA’s approval, which he called a sign that Western scientific minds are broadening.
“Like the population as a whole, the FDA has, in recent years, become more aware of integrative, complementary medicine and has shown more of a willingness to find ways to study these approaches,” he said. “But they’re still as rigorous as they are for pharmaceuticals.”
To learn more or enroll in the MACH-19 trials, visit clinicaltrials.gov and search for “MACH-19.”
